Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...
In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...
Investor's Business Daily on MSN4mon
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For DupixentOhtuvayre is the first inhaled treatment for ... near-term inflection with Dupixent in COPD treatment and a "meaningful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback